$VRTX News

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead

Are Wall Street Analysts Bullish on Vertex Stock?

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

Vertex (VRTX) Q2 2026 Earnings Call Transcript

Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails

Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617

Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says

Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says